Next Article in Journal
Preparation, Characterisation, and Topical Delivery of Terbinafine
Next Article in Special Issue
Polymeric Nanoparticles Based on Tyrosine-Modified, Low Molecular Weight Polyethylenimines for siRNA Delivery
Previous Article in Journal
Structure and Dynamics of a Site-Specific Labeled Fc Fragment with Altered Effector Functions
Previous Article in Special Issue
Intracellular Delivery of siRNAs Targeting AKT and ERBB2 Genes Enhances Chemosensitization of Breast Cancer Cells in a Culture and Animal Model
Review

Strategies for Delivery of siRNAs to Ovarian Cancer Cells

1
Department of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447, I-34149 Trieste, Italy
2
Department of Engineering and Architecture, University of Trieste, Via Valerio 6/A, I-34127 Trieste, Italy
3
Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, I-34127 Trieste, Italy
4
Pathology Unit, IRCCS CRO Aviano-National Cancer Institute, I-33081 Aviano, Italy
5
Doctoral School in Molecular Biomedicine, University of Trieste, I-34127 Trieste, Italy
6
Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, I-30123 Venezia-Mestre, Italy
7
International Clinical Research Center (ICRC), St Anne’s University Hospital, CZ-65691 Brno, Czech Republic
8
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume, 447, I-34149 Trieste, Italy
9
Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska 2, SI-1000 Ljubljana, Slovenia
10
Faculty of Health Sciences, University of Primorska, Polje 42, SI-6310 Izola, Slovenia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceutics 2019, 11(10), 547; https://doi.org/10.3390/pharmaceutics11100547
Received: 20 September 2019 / Revised: 15 October 2019 / Accepted: 18 October 2019 / Published: 22 October 2019
(This article belongs to the Special Issue Drug Delivery of siRNA Therapeutics)
The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. View Full-Text
Keywords: ovarian cancer; siRNA; polymer; lipid; delivery ovarian cancer; siRNA; polymer; lipid; delivery
Show Figures

Figure 1

MDPI and ACS Style

Farra, R.; Maruna, M.; Perrone, F.; Grassi, M.; Benedetti, F.; Maddaloni, M.; El Boustani, M.; Parisi, S.; Rizzolio, F.; Forte, G.; Zanconati, F.; Cemazar, M.; Kamensek, U.; Dapas, B.; Grassi, G. Strategies for Delivery of siRNAs to Ovarian Cancer Cells. Pharmaceutics 2019, 11, 547. https://doi.org/10.3390/pharmaceutics11100547

AMA Style

Farra R, Maruna M, Perrone F, Grassi M, Benedetti F, Maddaloni M, El Boustani M, Parisi S, Rizzolio F, Forte G, Zanconati F, Cemazar M, Kamensek U, Dapas B, Grassi G. Strategies for Delivery of siRNAs to Ovarian Cancer Cells. Pharmaceutics. 2019; 11(10):547. https://doi.org/10.3390/pharmaceutics11100547

Chicago/Turabian Style

Farra, Rossella, Matea Maruna, Francesca Perrone, Mario Grassi, Fabio Benedetti, Marianna Maddaloni, Maguie El Boustani, Salvo Parisi, Flavio Rizzolio, Giancarlo Forte, Fabrizio Zanconati, Maja Cemazar, Urska Kamensek, Barbara Dapas, and Gabriele Grassi. 2019. "Strategies for Delivery of siRNAs to Ovarian Cancer Cells" Pharmaceutics 11, no. 10: 547. https://doi.org/10.3390/pharmaceutics11100547

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop